These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16421797)

  • 1. The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations.
    Drusano GL; Louie A; Deziel M; Gumbo T
    Clin Infect Dis; 2006 Feb; 42(4):525-32. PubMed ID: 16421797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.
    Jumbe N; Louie A; Leary R; Liu W; Deziel MR; Tam VH; Bachhawat R; Freeman C; Kahn JB; Bush K; Dudley MN; Miller MH; Drusano GL
    J Clin Invest; 2003 Jul; 112(2):275-85. PubMed ID: 12865415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of antimicrobials.
    Drusano GL
    Clin Infect Dis; 2007 Jul; 45 Suppl 1():S89-95. PubMed ID: 17582578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa.
    Tam VH; Louie A; Deziel MR; Liu W; Leary R; Drusano GL
    J Infect Dis; 2005 Aug; 192(3):420-8. PubMed ID: 15995955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics: relation to antimicrobial resistance.
    Rybak MJ
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S38-45; discussion S64-73. PubMed ID: 16813981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.
    Tam VH; Louie A; Fritsche TR; Deziel M; Liu W; Brown DL; Deshpande L; Leary R; Jones RN; Drusano GL
    J Infect Dis; 2007 Jun; 195(12):1818-27. PubMed ID: 17492598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance.
    Tam VH; Louie A; Deziel MR; Liu W; Drusano GL
    Antimicrob Agents Chemother; 2007 Feb; 51(2):744-7. PubMed ID: 17116679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus.
    Drusano GL; Liu W; Brown DL; Rice LB; Louie A
    J Infect Dis; 2009 Jan; 199(2):219-26. PubMed ID: 19049435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
    Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
    Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical modelling response of Pseudomonas aeruginosa to meropenem.
    Tam VH; Schilling AN; Poole K; Nikolaou M
    J Antimicrob Chemother; 2007 Dec; 60(6):1302-9. PubMed ID: 17913722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinolones in 2005: an update.
    Van Bambeke F; Michot JM; Van Eldere J; Tulkens PM
    Clin Microbiol Infect; 2005 Apr; 11(4):256-80. PubMed ID: 15760423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial resistance and the food chain.
    Teale CJ
    J Appl Microbiol; 2002; 92 Suppl():85S-9S. PubMed ID: 12000617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.
    Zhao X; Drlica K
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S147-56. PubMed ID: 11524712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The rate of inducible clindamycin resistance and susceptibilities to other antimicrobial agents in staphylococci].
    Oğuz VA; Yapar N; Sezak N; Cavuş SA; Kurutepe S; Peksel H; Cakir N; Yüce A
    Mikrobiyol Bul; 2009 Jan; 43(1):37-44. PubMed ID: 19334378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models.
    Smirnova MV; Vostrov SN; Strukova EV; Dovzhenko SA; Kobrin MB; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2009 Oct; 64(4):815-20. PubMed ID: 19671586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usage of antimicrobials and occurrence of antimicrobial resistance among bacteria from mink.
    Pedersen K; Hammer AS; Sørensen CM; Heuer OE
    Vet Microbiol; 2009 Jan; 133(1-2):115-22. PubMed ID: 18620819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A network-based approach for resistance transmission in bacterial populations.
    Gehring R; Schumm P; Youssef M; Scoglio C
    J Theor Biol; 2010 Jan; 262(1):97-106. PubMed ID: 19747924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albomycin is an effective antibiotic, as exemplified with Yersinia enterocolitica and Streptococcus pneumoniae.
    Pramanik A; Stroeher UH; Krejci J; Standish AJ; Bohn E; Paton JC; Autenrieth IB; Braun V
    Int J Med Microbiol; 2007 Oct; 297(6):459-69. PubMed ID: 17459767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.